Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 16/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787520 | 0.90 | JAK2 (0.37) | HCAR2CHEK1 | |
| SCHEMBL6788457 | 0.83 | HCAR2 (0.39) | HCAR2 | |
| SCHEMBL6793773 | 0.79 | HCAR2 (0.48) | HCAR2 | |
| SCHEMBL6790823 | 0.74 | JAK2 (0.36) | CHEK1 | |
| SCHEMBL6786978 | 0.70 | ALDH1A1 (0.41) | HCAR2CHEK1 | |
| SCHEMBL6793173 | 0.65 | MEN1 (0.43) | HCAR2CHEK1GRK6 | |
| SCHEMBL4790859 | 0.61 | DYRK1A (0.50) | — | |
| SCHEMBL4483250 | 0.61 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL3520429 | 0.59 | HCAR2 (0.41) | HCAR2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL6280866 | 0.59 | HSP90AA1 (0.50) | CHEK1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | HCAR2 1767/4885CHEK1 427/4885PRKAB2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.